|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック， インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
SG10202112838YA
(en)
|
2008-04-09 |
2021-12-30 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
EP3169363A4
(en)
*
|
2014-07-16 |
2018-02-21 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US20160152720A1
(en)
*
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
JP6180663B2
(ja)
*
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
SG11201705844SA
(en)
*
|
2015-02-06 |
2017-08-30 |
Heat Biologics Inc |
Vector co-expressing vaccine and costimulatory molecules
|
|
US10196445B1
(en)
|
2015-03-17 |
2019-02-05 |
Bristol-Myers Squibb Company |
Ipilimumab variant with enhanced ADCC
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
MX2017015260A
(es)
|
2015-06-03 |
2018-02-19 |
Squibb Bristol Myers Co |
Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
|
|
MX2017015937A
(es)
*
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
|
JP2018521019A
(ja)
*
|
2015-06-08 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体を使用して癌を治療する方法
|
|
JP2018516969A
(ja)
|
2015-06-12 |
2018-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US10786547B2
(en)
|
2015-07-16 |
2020-09-29 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
|
MX2018000948A
(es)
*
|
2015-07-23 |
2018-09-27 |
Inhibrx Inc |
Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
|
|
EP3331917A1
(en)
*
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
CN108290936B
(zh)
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
PE20181046A1
(es)
|
2015-09-25 |
2018-07-03 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso
|
|
PT3356413T
(pt)
|
2015-10-01 |
2022-04-04 |
Potenza Therapeutics Inc |
Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
ES2979210T3
(es)
*
|
2015-12-15 |
2024-09-24 |
Oncoc4 Inc |
Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
|
|
US10537633B2
(en)
|
2016-03-04 |
2020-01-21 |
Jn Biosciences Llc |
Antibodies to TIGIT
|
|
WO2017165412A2
(en)
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
|
CA3021634A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Zymeworks Inc. |
Multi-specific antigen-binding constructs targeting immunotherapeutics
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
EP3464360B1
(en)
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
FR3051794A1
(fr)
*
|
2016-05-31 |
2017-12-01 |
Lab Francais Du Fractionnement |
Anticorps pour le traitement de cancers
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
US11858996B2
(en)
|
2016-08-09 |
2024-01-02 |
Kymab Limited |
Anti-ICOS antibodies
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
MY200695A
(en)
*
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
DK3551660T5
(da)
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
CN110536693B
(zh)
*
|
2017-01-05 |
2023-12-22 |
卡尔医学有限公司 |
Pd1-41bbl融合蛋白及使用其的方法
|
|
RU2769769C2
(ru)
|
2017-01-05 |
2022-04-05 |
Кахр Медикал Лтд. |
СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
|
|
CA3051839A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
|
AU2018227428A1
(en)
|
2017-02-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
|
|
PE20250933A1
(es)
|
2017-03-14 |
2025-04-02 |
Five Prime Therapeutics Inc |
Anticuerpos de union a vista a ph acido
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
CN110869392A
(zh)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
用抗gitr激动性抗体治疗癌症
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
WO2019008375A1
(en)
*
|
2017-07-06 |
2019-01-10 |
Ucl Business Plc |
Method for identifying responders to cancer treatment
|
|
IL272227B2
(en)
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
JP7317272B2
(ja)
|
2017-09-29 |
2023-07-31 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
|
|
BR112020007542A2
(pt)
|
2017-10-18 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
TWI877769B
(zh)
|
2017-12-30 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
IT201800001315A1
(it)
*
|
2018-01-18 |
2019-07-18 |
Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro |
Nuovi agenti terapeutici antitumorali
|
|
KR102834864B1
(ko)
*
|
2018-02-02 |
2025-07-16 |
온코씨4, 아이앤씨. |
개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
|
|
WO2019152413A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Oncoimmune, Inc. |
Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
|
KR20260046525A
(ko)
|
2018-04-11 |
2026-04-07 |
인히브릭스 바이오사이언스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
|
EP3820887A4
(en)
|
2018-07-11 |
2022-04-20 |
KAHR Medical Ltd. |
Pd1-4-1bbl variant fusion protein and methods of use thereof
|
|
KR102945860B1
(ko)
|
2018-07-11 |
2026-03-31 |
카 메디컬 리미티드 |
SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
|
|
GB201811408D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
ES3044118T3
(en)
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
US20210361706A1
(en)
*
|
2018-08-29 |
2021-11-25 |
Academia Sinica |
Combination of natural killer cells with cyclophosphamide compounds for the treatment of cancer
|
|
JP2022512642A
(ja)
|
2018-10-09 |
2022-02-07 |
ブリストル－マイヤーズ スクイブ カンパニー |
がんを治療するための抗ＭｅｒＴＫ抗体
|
|
SG11202106764YA
(en)
*
|
2018-12-27 |
2021-07-29 |
Gigagen Inc |
Anti-ctla-4 binding proteins and methods of use thereof
|
|
WO2020185722A2
(en)
|
2019-03-13 |
2020-09-17 |
Merck Sharp & Dohme Corp. |
Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
|
|
CA3149719A1
(en)
*
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
CA3170025A1
(en)
|
2020-03-13 |
2021-09-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pvrig binding protein and its medical uses
|
|
PE20230255A1
(es)
|
2020-04-17 |
2023-02-07 |
Hutchison Medipharma Ltd |
Anticuerpo anti-ox40 y usos del mismo
|
|
AR122043A1
(es)
*
|
2020-05-12 |
2022-08-03 |
Bristol Myers Squibb Co |
Dosificación y administración del anticuerpo anti-ctla-4 activable
|
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
|
KR20230033719A
(ko)
*
|
2020-07-02 |
2023-03-08 |
기가젠, 인코포레이티드 |
항-ctla-4 결합 단백질 및 이의 사용 방법
|
|
CN121668303A
(zh)
|
2020-10-11 |
2026-03-17 |
百奥泰生物制药股份有限公司 |
抗pd-1抗体在联合用药中的应用
|
|
CN116390949A
(zh)
|
2020-11-06 |
2023-07-04 |
百时美施贵宝公司 |
作为单一疗法给药和施用非岩藻糖基化抗ctla-4抗体
|
|
TW202313682A
(zh)
|
2021-05-18 |
2023-04-01 |
英商凱麥博有限公司 |
抗icos抗體之用途
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
EP4403573A4
(en)
|
2021-09-15 |
2024-12-25 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY
|
|
EP4403574A4
(en)
|
2021-09-15 |
2025-10-29 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
PD-1-Specific Protein and Its Pharmaceutical Use
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
US20260048119A1
(en)
|
2022-08-05 |
2026-02-19 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibodies for treatment of kras mutant cancers
|
|
KR20250156744A
(ko)
|
2023-03-15 |
2025-11-03 |
상하이 맙젠 바이오텍 리미티드 |
Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
|
|
KR20250026280A
(ko)
*
|
2023-06-30 |
2025-02-25 |
카이미 바이오메디신 (청두) 컴퍼니 리미티드 |
글리코실 변형을 거친 융합 단백질, 핵산 분자, 발현 벡터, 숙주 세포 및 응용
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|